TocilizumabV1, Main, Exploration, bibRecord, 001C43

CD126 and Targeted Therapy with Tocilizumab in Chronic Lymphocytic Leukemia.

Identifieur interne : 001C43 ( Main/Exploration ); précédent : 001C42; suivant : 001C44

CD126 and Targeted Therapy with Tocilizumab in Chronic Lymphocytic Leukemia.

Auteurs : Feng-Ting Liu [République populaire de Chine] ; Li Jia [Royaume-Uni] ; Ping Wang [République populaire de Chine] ; Timothy Farren [Royaume-Uni] ; Hong Li [Royaume-Uni] ; Xishan Hao [République populaire de Chine] ; Samir G. Agrawal [Royaume-Uni]

Source :

Clinical cancer research : an official journal of the American Association for Cancer Research [ 1078-0432 ] ; 2016.

RBID : pubmed:26712690

Descripteurs français

English descriptors

KwdEn :
- Adult, Aged, Aged, 80 and over, Antibodies, Monoclonal, Humanized (therapeutic use), Antineoplastic Agents (therapeutic use), B-Lymphocytes (drug effects), B-Lymphocytes (metabolism), Cell Cycle (drug effects), Cyclin E (metabolism), Cyclin-Dependent Kinase 2 (metabolism), Drug Resistance, Neoplasm (drug effects), Female, Humans, Interleukin-6 (metabolism), Leukemia, Lymphocytic, Chronic, B-Cell (drug therapy), Leukemia, Lymphocytic, Chronic, B-Cell (metabolism), Male, Middle Aged, Molecular Targeted Therapy (methods), Myeloid Cell Leukemia Sequence 1 Protein (metabolism), Proliferating Cell Nuclear Antigen (metabolism), Receptors, Interleukin-6 (metabolism), STAT3 Transcription Factor (metabolism), Tumor Cells, Cultured, bcl-X Protein (metabolism).
MESH :
- chemical , metabolism : Cyclin E, Cyclin-Dependent Kinase 2, Interleukin-6, Myeloid Cell Leukemia Sequence 1 Protein, Proliferating Cell Nuclear Antigen, Receptors, Interleukin-6, STAT3 Transcription Factor, bcl-X Protein.
- chemical , therapeutic use : Antibodies, Monoclonal, Humanized, Antineoplastic Agents.
- drug effects : B-Lymphocytes, Cell Cycle, Drug Resistance, Neoplasm.
- drug therapy : Leukemia, Lymphocytic, Chronic, B-Cell.
- metabolism : B-Lymphocytes, Leukemia, Lymphocytic, Chronic, B-Cell.
- methods : Molecular Targeted Therapy.
- Adult, Aged, Aged, 80 and over, Female, Humans, Male, Middle Aged, Tumor Cells, Cultured.

Abstract

IL6 promotes tumor growth and signal transduction via both its membrane-bound (CD126) and soluble receptors (sCD126). We aimed to study whether the levels of CD126 expression in chronic lymphocytic leukemic (CLL) cells can predict in vitro and in vivo treatment response.

DOI: 10.1158/1078-0432.CCR-15-1139
PubMed: 26712690

Affiliations:

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">CD126 and Targeted Therapy with Tocilizumab in Chronic Lymphocytic Leukemia.</title>
<author><name sortKey="Liu, Feng Ting" sort="Liu, Feng Ting" uniqKey="Liu F" first="Feng-Ting" last="Liu">Feng-Ting Liu</name>
<affiliation wicri:level="3"><nlm:affiliation>Department of Radiobiology, Key Laboratory of Cancer Prevention and Therapy, National Clinical Research Centre for Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China. liufengting@tjmuch.com s.g.agrawal@qmul.ac.uk.</nlm:affiliation>
<country xml:lang="fr">République populaire de Chine</country>
<wicri:regionArea>Department of Radiobiology, Key Laboratory of Cancer Prevention and Therapy, National Clinical Research Centre for Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin</wicri:regionArea>
<placeName><settlement type="city">Tianjin</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Jia, Li" sort="Jia, Li" uniqKey="Jia L" first="Li" last="Jia">Li Jia</name>
<affiliation wicri:level="4"><nlm:affiliation>Centre for Haemato-Oncology, Barts Cancer Institute, Queen Mary University of London, London, United Kingdom.</nlm:affiliation>
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Centre for Haemato-Oncology, Barts Cancer Institute, Queen Mary University of London, London</wicri:regionArea>
<placeName><settlement type="city">Londres</settlement>
<region type="country">Angleterre</region>
<region type="région" nuts="1">Grand Londres</region>
</placeName>
<orgName type="university">Université de Londres</orgName>
</affiliation>
</author>
<author><name sortKey="Wang, Ping" sort="Wang, Ping" uniqKey="Wang P" first="Ping" last="Wang">Ping Wang</name>
<affiliation wicri:level="3"><nlm:affiliation>Department of Radiobiology, Key Laboratory of Cancer Prevention and Therapy, National Clinical Research Centre for Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China.</nlm:affiliation>
<country xml:lang="fr">République populaire de Chine</country>
<wicri:regionArea>Department of Radiobiology, Key Laboratory of Cancer Prevention and Therapy, National Clinical Research Centre for Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin</wicri:regionArea>
<placeName><settlement type="city">Tianjin</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Farren, Timothy" sort="Farren, Timothy" uniqKey="Farren T" first="Timothy" last="Farren">Timothy Farren</name>
<affiliation wicri:level="4"><nlm:affiliation>Division of Haemato-Oncology, St Bartholomew's Hospital, Barts Health NHS Trust, London, United Kingdom. Pathology Group, Blizard Institute, Queen Mary University of London, London, United Kingdom.</nlm:affiliation>
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Division of Haemato-Oncology, St Bartholomew's Hospital, Barts Health NHS Trust, London, United Kingdom. Pathology Group, Blizard Institute, Queen Mary University of London, London</wicri:regionArea>
<placeName><settlement type="city">Londres</settlement>
<region type="country">Angleterre</region>
<region type="région" nuts="1">Grand Londres</region>
</placeName>
<orgName type="university">Université de Londres</orgName>
</affiliation>
</author>
<author><name sortKey="Li, Hong" sort="Li, Hong" uniqKey="Li H" first="Hong" last="Li">Hong Li</name>
<affiliation wicri:level="4"><nlm:affiliation>Department of Pathology, King's College University of London, London, United Kingdom.</nlm:affiliation>
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Department of Pathology, King's College University of London, London</wicri:regionArea>
<placeName><settlement type="city">Londres</settlement>
<region type="country">Angleterre</region>
<region type="région" nuts="1">Grand Londres</region>
</placeName>
<orgName type="university">Université de Londres</orgName>
</affiliation>
</author>
<author><name sortKey="Hao, Xishan" sort="Hao, Xishan" uniqKey="Hao X" first="Xishan" last="Hao">Xishan Hao</name>
<affiliation wicri:level="3"><nlm:affiliation>Department of Radiobiology, Key Laboratory of Cancer Prevention and Therapy, National Clinical Research Centre for Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China.</nlm:affiliation>
<country xml:lang="fr">République populaire de Chine</country>
<wicri:regionArea>Department of Radiobiology, Key Laboratory of Cancer Prevention and Therapy, National Clinical Research Centre for Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin</wicri:regionArea>
<placeName><settlement type="city">Tianjin</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Agrawal, Samir G" sort="Agrawal, Samir G" uniqKey="Agrawal S" first="Samir G" last="Agrawal">Samir G. Agrawal</name>
<affiliation wicri:level="4"><nlm:affiliation>Centre for Haemato-Oncology, Barts Cancer Institute, Queen Mary University of London, London, United Kingdom. Division of Haemato-Oncology, St Bartholomew's Hospital, Barts Health NHS Trust, London, United Kingdom. liufengting@tjmuch.com s.g.agrawal@qmul.ac.uk.</nlm:affiliation>
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Centre for Haemato-Oncology, Barts Cancer Institute, Queen Mary University of London, London, United Kingdom. Division of Haemato-Oncology, St Bartholomew's Hospital, Barts Health NHS Trust, London</wicri:regionArea>
<placeName><settlement type="city">Londres</settlement>
<region type="country">Angleterre</region>
<region type="région" nuts="1">Grand Londres</region>
</placeName>
<orgName type="university">Université de Londres</orgName>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2016">2016</date>
<idno type="RBID">pubmed:26712690</idno>
<idno type="pmid">26712690</idno>
<idno type="doi">10.1158/1078-0432.CCR-15-1139</idno>
<idno type="wicri:Area/PubMed/Corpus">000F89</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000F89</idno>
<idno type="wicri:Area/PubMed/Curation">000F89</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000F89</idno>
<idno type="wicri:Area/PubMed/Checkpoint">000F11</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000F11</idno>
<idno type="wicri:Area/Ncbi/Merge">001022</idno>
<idno type="wicri:Area/Ncbi/Curation">001022</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">001022</idno>
<idno type="wicri:doubleKey">1078-0432:2016:Liu F:cd:and:targeted</idno>
<idno type="wicri:Area/Main/Merge">001C43</idno>
<idno type="wicri:Area/Main/Curation">001C43</idno>
<idno type="wicri:Area/Main/Exploration">001C43</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">CD126 and Targeted Therapy with Tocilizumab in Chronic Lymphocytic Leukemia.</title>
<author><name sortKey="Liu, Feng Ting" sort="Liu, Feng Ting" uniqKey="Liu F" first="Feng-Ting" last="Liu">Feng-Ting Liu</name>
<affiliation wicri:level="3"><nlm:affiliation>Department of Radiobiology, Key Laboratory of Cancer Prevention and Therapy, National Clinical Research Centre for Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China. liufengting@tjmuch.com s.g.agrawal@qmul.ac.uk.</nlm:affiliation>
<country xml:lang="fr">République populaire de Chine</country>
<wicri:regionArea>Department of Radiobiology, Key Laboratory of Cancer Prevention and Therapy, National Clinical Research Centre for Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin</wicri:regionArea>
<placeName><settlement type="city">Tianjin</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Jia, Li" sort="Jia, Li" uniqKey="Jia L" first="Li" last="Jia">Li Jia</name>
<affiliation wicri:level="4"><nlm:affiliation>Centre for Haemato-Oncology, Barts Cancer Institute, Queen Mary University of London, London, United Kingdom.</nlm:affiliation>
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Centre for Haemato-Oncology, Barts Cancer Institute, Queen Mary University of London, London</wicri:regionArea>
<placeName><settlement type="city">Londres</settlement>
<region type="country">Angleterre</region>
<region type="région" nuts="1">Grand Londres</region>
</placeName>
<orgName type="university">Université de Londres</orgName>
</affiliation>
</author>
<author><name sortKey="Wang, Ping" sort="Wang, Ping" uniqKey="Wang P" first="Ping" last="Wang">Ping Wang</name>
<affiliation wicri:level="3"><nlm:affiliation>Department of Radiobiology, Key Laboratory of Cancer Prevention and Therapy, National Clinical Research Centre for Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China.</nlm:affiliation>
<country xml:lang="fr">République populaire de Chine</country>
<wicri:regionArea>Department of Radiobiology, Key Laboratory of Cancer Prevention and Therapy, National Clinical Research Centre for Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin</wicri:regionArea>
<placeName><settlement type="city">Tianjin</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Farren, Timothy" sort="Farren, Timothy" uniqKey="Farren T" first="Timothy" last="Farren">Timothy Farren</name>
<affiliation wicri:level="4"><nlm:affiliation>Division of Haemato-Oncology, St Bartholomew's Hospital, Barts Health NHS Trust, London, United Kingdom. Pathology Group, Blizard Institute, Queen Mary University of London, London, United Kingdom.</nlm:affiliation>
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Division of Haemato-Oncology, St Bartholomew's Hospital, Barts Health NHS Trust, London, United Kingdom. Pathology Group, Blizard Institute, Queen Mary University of London, London</wicri:regionArea>
<placeName><settlement type="city">Londres</settlement>
<region type="country">Angleterre</region>
<region type="région" nuts="1">Grand Londres</region>
</placeName>
<orgName type="university">Université de Londres</orgName>
</affiliation>
</author>
<author><name sortKey="Li, Hong" sort="Li, Hong" uniqKey="Li H" first="Hong" last="Li">Hong Li</name>
<affiliation wicri:level="4"><nlm:affiliation>Department of Pathology, King's College University of London, London, United Kingdom.</nlm:affiliation>
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Department of Pathology, King's College University of London, London</wicri:regionArea>
<placeName><settlement type="city">Londres</settlement>
<region type="country">Angleterre</region>
<region type="région" nuts="1">Grand Londres</region>
</placeName>
<orgName type="university">Université de Londres</orgName>
</affiliation>
</author>
<author><name sortKey="Hao, Xishan" sort="Hao, Xishan" uniqKey="Hao X" first="Xishan" last="Hao">Xishan Hao</name>
<affiliation wicri:level="3"><nlm:affiliation>Department of Radiobiology, Key Laboratory of Cancer Prevention and Therapy, National Clinical Research Centre for Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China.</nlm:affiliation>
<country xml:lang="fr">République populaire de Chine</country>
<wicri:regionArea>Department of Radiobiology, Key Laboratory of Cancer Prevention and Therapy, National Clinical Research Centre for Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin</wicri:regionArea>
<placeName><settlement type="city">Tianjin</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Agrawal, Samir G" sort="Agrawal, Samir G" uniqKey="Agrawal S" first="Samir G" last="Agrawal">Samir G. Agrawal</name>
<affiliation wicri:level="4"><nlm:affiliation>Centre for Haemato-Oncology, Barts Cancer Institute, Queen Mary University of London, London, United Kingdom. Division of Haemato-Oncology, St Bartholomew's Hospital, Barts Health NHS Trust, London, United Kingdom. liufengting@tjmuch.com s.g.agrawal@qmul.ac.uk.</nlm:affiliation>
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Centre for Haemato-Oncology, Barts Cancer Institute, Queen Mary University of London, London, United Kingdom. Division of Haemato-Oncology, St Bartholomew's Hospital, Barts Health NHS Trust, London</wicri:regionArea>
<placeName><settlement type="city">Londres</settlement>
<region type="country">Angleterre</region>
<region type="région" nuts="1">Grand Londres</region>
</placeName>
<orgName type="university">Université de Londres</orgName>
</affiliation>
</author>
</analytic>
<series><title level="j">Clinical cancer research : an official journal of the American Association for Cancer Research</title>
<idno type="ISSN">1078-0432</idno>
<imprint><date when="2016" type="published">2016</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term>
<term>Aged</term>
<term>Aged, 80 and over</term>
<term>Antibodies, Monoclonal, Humanized (therapeutic use)</term>
<term>Antineoplastic Agents (therapeutic use)</term>
<term>B-Lymphocytes (drug effects)</term>
<term>B-Lymphocytes (metabolism)</term>
<term>Cell Cycle (drug effects)</term>
<term>Cyclin E (metabolism)</term>
<term>Cyclin-Dependent Kinase 2 (metabolism)</term>
<term>Drug Resistance, Neoplasm (drug effects)</term>
<term>Female</term>
<term>Humans</term>
<term>Interleukin-6 (metabolism)</term>
<term>Leukemia, Lymphocytic, Chronic, B-Cell (drug therapy)</term>
<term>Leukemia, Lymphocytic, Chronic, B-Cell (metabolism)</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Molecular Targeted Therapy (methods)</term>
<term>Myeloid Cell Leukemia Sequence 1 Protein (metabolism)</term>
<term>Proliferating Cell Nuclear Antigen (metabolism)</term>
<term>Receptors, Interleukin-6 (metabolism)</term>
<term>STAT3 Transcription Factor (metabolism)</term>
<term>Tumor Cells, Cultured</term>
<term>bcl-X Protein (metabolism)</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>Adulte</term>
<term>Adulte d'âge moyen</term>
<term>Anticorps monoclonaux humanisés (usage thérapeutique)</term>
<term>Antigène nucléaire de prolifération cellulaire (métabolisme)</term>
<term>Antinéoplasiques (usage thérapeutique)</term>
<term>Cellules cancéreuses en culture</term>
<term>Cycle cellulaire ()</term>
<term>Cycline E (métabolisme)</term>
<term>Facteur de transcription STAT-3 (métabolisme)</term>
<term>Femelle</term>
<term>Humains</term>
<term>Interleukine-6 (métabolisme)</term>
<term>Kinase-2 cycline-dépendante (métabolisme)</term>
<term>Leucémie chronique lymphocytaire à cellules B (métabolisme)</term>
<term>Leucémie chronique lymphocytaire à cellules B (traitement médicamenteux)</term>
<term>Lymphocytes B ()</term>
<term>Lymphocytes B (métabolisme)</term>
<term>Mâle</term>
<term>Protéine Mcl-1 (métabolisme)</term>
<term>Protéine bcl-X (métabolisme)</term>
<term>Récepteurs à l'interleukine-6 (métabolisme)</term>
<term>Résistance aux médicaments antinéoplasiques ()</term>
<term>Sujet âgé</term>
<term>Sujet âgé de 80 ans ou plus</term>
<term>Thérapie moléculaire ciblée ()</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>Cyclin E</term>
<term>Cyclin-Dependent Kinase 2</term>
<term>Interleukin-6</term>
<term>Myeloid Cell Leukemia Sequence 1 Protein</term>
<term>Proliferating Cell Nuclear Antigen</term>
<term>Receptors, Interleukin-6</term>
<term>STAT3 Transcription Factor</term>
<term>bcl-X Protein</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antibodies, Monoclonal, Humanized</term>
<term>Antineoplastic Agents</term>
</keywords>
<keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>B-Lymphocytes</term>
<term>Cell Cycle</term>
<term>Drug Resistance, Neoplasm</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Leukemia, Lymphocytic, Chronic, B-Cell</term>
</keywords>
<keywords scheme="MESH" qualifier="metabolism" xml:lang="en"><term>B-Lymphocytes</term>
<term>Leukemia, Lymphocytic, Chronic, B-Cell</term>
</keywords>
<keywords scheme="MESH" qualifier="methods" xml:lang="en"><term>Molecular Targeted Therapy</term>
</keywords>
<keywords scheme="MESH" qualifier="métabolisme" xml:lang="fr"><term>Antigène nucléaire de prolifération cellulaire</term>
<term>Cycline E</term>
<term>Facteur de transcription STAT-3</term>
<term>Interleukine-6</term>
<term>Kinase-2 cycline-dépendante</term>
<term>Leucémie chronique lymphocytaire à cellules B</term>
<term>Lymphocytes B</term>
<term>Protéine Mcl-1</term>
<term>Protéine bcl-X</term>
<term>Récepteurs à l'interleukine-6</term>
</keywords>
<keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Leucémie chronique lymphocytaire à cellules B</term>
</keywords>
<keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Anticorps monoclonaux humanisés</term>
<term>Antinéoplasiques</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Adult</term>
<term>Aged</term>
<term>Aged, 80 and over</term>
<term>Female</term>
<term>Humans</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Tumor Cells, Cultured</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>Adulte</term>
<term>Adulte d'âge moyen</term>
<term>Cellules cancéreuses en culture</term>
<term>Cycle cellulaire</term>
<term>Femelle</term>
<term>Humains</term>
<term>Lymphocytes B</term>
<term>Mâle</term>
<term>Résistance aux médicaments antinéoplasiques</term>
<term>Sujet âgé</term>
<term>Sujet âgé de 80 ans ou plus</term>
<term>Thérapie moléculaire ciblée</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">IL6 promotes tumor growth and signal transduction via both its membrane-bound (CD126) and soluble receptors (sCD126). We aimed to study whether the levels of CD126 expression in chronic lymphocytic leukemic (CLL) cells can predict in vitro and in vivo treatment response.</div>
</front>
</TEI>
<affiliations><list><country><li>Royaume-Uni</li>
<li>République populaire de Chine</li>
</country>
<region><li>Angleterre</li>
<li>Grand Londres</li>
</region>
<settlement><li>Londres</li>
<li>Tianjin</li>
</settlement>
<orgName><li>Université de Londres</li>
</orgName>
</list>
<tree><country name="République populaire de Chine"><noRegion><name sortKey="Liu, Feng Ting" sort="Liu, Feng Ting" uniqKey="Liu F" first="Feng-Ting" last="Liu">Feng-Ting Liu</name>
</noRegion>
<name sortKey="Hao, Xishan" sort="Hao, Xishan" uniqKey="Hao X" first="Xishan" last="Hao">Xishan Hao</name>
<name sortKey="Wang, Ping" sort="Wang, Ping" uniqKey="Wang P" first="Ping" last="Wang">Ping Wang</name>
</country>
<country name="Royaume-Uni"><region name="Angleterre"><name sortKey="Jia, Li" sort="Jia, Li" uniqKey="Jia L" first="Li" last="Jia">Li Jia</name>
</region>
<name sortKey="Agrawal, Samir G" sort="Agrawal, Samir G" uniqKey="Agrawal S" first="Samir G" last="Agrawal">Samir G. Agrawal</name>
<name sortKey="Farren, Timothy" sort="Farren, Timothy" uniqKey="Farren T" first="Timothy" last="Farren">Timothy Farren</name>
<name sortKey="Li, Hong" sort="Li, Hong" uniqKey="Li H" first="Hong" last="Li">Hong Li</name>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/TocilizumabV1/Data/Main/Exploration

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001C43 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 001C43 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    TocilizumabV1
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     pubmed:26712690
   |texte=   CD126 and Targeted Therapy with Tocilizumab in Chronic Lymphocytic Leukemia.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i   -Sk "pubmed:26712690" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd   \
       | NlmPubMed2Wicri -a TocilizumabV1

This area was generated with Dilib version V0.6.34.
Data generation: Fri May 22 09:34:00 2020. Site generation: Sun Mar 28 09:01:19 2021

Serveur d'exploration Tocilizumab

CD126 and Targeted Therapy with Tocilizumab in Chronic Lymphocytic Leukemia.

CD126 and Targeted Therapy with Tocilizumab in Chronic Lymphocytic Leukemia.

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki

	Serveur d'exploration Tocilizumab
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.